# Naporafenib

Source: https://onco.cc/drugs/naporafenib/  
OnCo record `naporafenib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.

## Summary

Naporafenib (ERAS-254, LXH254) is a small-molecule drug developed by Erasca. The sponsor describes its target as RAF (pan-RAF), which OnCo does not yet have a target page for. The sponsor states: An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma. ClinicalTrials.gov describes the intervention as: Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)), in melanoma. The largest, NCT06346067, plans to enrol 78 participants (actual) with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: ERAS-254, LXH254
- Modality: small molecule
- Mechanism: An experimental pan-RAF inhibitor blocking RAF kinase signalling in the MAPK pathway, studied in combination with the MEK inhibitor trametinib in NRAS-mutant melanoma.

## Sources

- ClinicalTrials.gov: trials of Naporafenib: https://clinicaltrials.gov/search?intr=ERAS-254

## Connected records

- cancers: [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Mucosal melanoma](https://onco.cc/cancers/mucosal-melanoma/)
- companies: [Erasca](https://onco.cc/companies/erasca/)
- trials: [A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)](https://onco.cc/trials/seacraft-2/), [Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct04417621/)
- targets: [NRAS](https://onco.cc/targets/nras/)

---
JSON: https://onco.cc/api/v1/entities/naporafenib.json